BridgeBio Pharma IncNASDAQ:BBIO
- LAST PRICE27.8250
- TODAY'S CHANGE (%)0.6350 (2.3354%)
- Bid / Lots27.7600/ 4
- Ask / Lots27.8900/ 5
- Open / Previous Close26.9300 / 27.1900
- Day Range
- 52 Week Range
- Volume121,477
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BBIO |
|---|---|---|
| 09:32 ET | 59375 | 27.325 |
| 09:33 ET | 8705 | 27.825 |
Yesterday
DJ BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank, from 15 hours ago by Dow Jones
15 hours ago by Dow JonesDJ BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk, from 19 hours ago by Dow Jones
19 hours ago by Dow JonesDJ BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby, from 9:10AM ET on Monday Nov 25, 2024 by Dow Jones
9:10AM ET on Monday Nov 25, 2024 by Dow JonesDJ BridgeBio Pharma Is Maintained at Buy by B of A Securities, from 8:21AM ET on Monday Nov 25, 2024 by Dow Jones
8:21AM ET on Monday Nov 25, 2024 by Dow JonesDJ BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co., from 8:04AM ET on Monday Nov 25, 2024 by Dow Jones
8:04AM ET on Monday Nov 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BridgeBio Pharma Inc | 4.4B | -11.5x | --- |
Biohaven Ltd | 4.6B | -4.9x | --- |
Immunovant Inc | 3.9B | -12.2x | --- |
Avidity Biosciences Inc | 5.2B | -15.8x | --- |
Crinetics Pharmaceuticals Inc | 5.2B | -15.2x | --- |
Immunitybio Inc | 3.6B | -5.7x | --- |
Company Information
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Contact Information
- Headquarters
- 3160 Porter Dr., Suite 250PALO ALTO, CA, United States 94304
- Phone
- 650-391-9740
- Fax
- 302-655-5049
Executives
- President, Chief Operating Officer
- Thomas Trimarchi
- Chief Executive Officer, Director
- Neil Kumar
- Chief Financial Officer, Secretary
- Brian Stephenson
- Lead Director, Chairman of Pharmaceuticals
- Charles Homcy
- Director
- Frank Mccormick
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4B |
|---|---|
Revenue (TTM) | $217.8M |
Shares Outstanding | 189.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-2.41 |
Book Value | $-7.73 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 20.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -180.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
